Video

Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
© 2025 MJH Life Sciences

All rights reserved.